Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care

Transfusion

Volumn 58, Issue 8, 2018, Pages 1881-1889

  Jimenez Marco, Teresa ^a   Garcia Recio, Marta ^b   Girona Llobera, Enrique ^a  

^a Fundació Banc de Sang i Teixits de les Illes Balears FBSTIB   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ADULT; ALLERGY; ARTICLE; BALEARIC ISLANDS; BLOOD STORAGE; CANCER PATIENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; FEMALE; FEVER; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; RETROSPECTIVE STUDY; SAFETY; SURGICAL PATIENT; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; ULTRAVIOLET RADIATION; BLOOD SAFETY; COST; COST BENEFIT ANALYSIS; ECONOMICS; PROCEDURES; QUALITY CONTROL;

BLOOD SAFETY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; PLATELET TRANSFUSION; QUALITY CONTROL; RETROSPECTIVE STUDIES; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 85052648711     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14797     Document Type: Article

References (46)

1. Drew VJ, Barro L, Seghatchian J, et al. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus 2017;15:512-21.
2. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33:1-7.
3. Muench MO, Heitman JW, Inglis H, et al. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets. Transfusion 2016;56:1419-29.
4. Jackman RP, Heitman JW, Marschner S, et al. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009;49:2686-9.
5. Łetowska M, Przybylska Z, Piotrowski D, et al. Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period. Transfusion 2016;56:S39-44.
6. Piotrowski D, Przybylska-Baluta Z, Jimenez-Marco T, et al. Passive haemovigilance of blood components treated with a riboflavin-based pathogen reduction technology. Blood Transfus 2017;23:1-4.
7. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014;54:158-68.
8. Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya? Lancet 2015;386:243-4.
9. le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999;37:1953-7.
10. Biglio A, Bola C, Concialdi E, et al. Asymptomatic Leishmania infantum infection in an area of north-western Italy (Piedmont region) where such infections are traditionally endemic. J Clin Microbiol 2010;48:131-6.
11. Riera C, Fisa R, López-Chejade P, et al. Asymptomatic infection by Leishmania Infantum in blood donors from the Balearic Islands (Spain). Transfusion 2008;48:1383-9.
12. Jimenez-Marco T, Riera C, Fisa R, et al. The utility of pathogen inactivation technology: a real-life example of Leishmania infantum inactivation in platelets from a donor with an asymptomatic infection. Blood Transfus 2012;10:536-41.
13. Jimenez-Marco T, Fisa R, Girona-Llobera E, et al. Transfusion-transmitted leishmaniasis: a practical review. Transfusion 2016;56:S45-51.
14. Jimenez-Marco T, Riera C, Girona-Llobera E, et al. Strategies for reducing the risk of transfusion-transmitted leishmaniasis in an area endemic for Leishmania infantum: a patient- and donor-targeted approach. Blood Transfus 2017;15:1-8.
15. Benjamin RJ, Stramer SL, Leiby DA, et al. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 2012;52:1913-21.
16. Cancino-Faure B, Fisa R, Riera C, et al. Evidence of meaningful levels of Trypanosoma cruzi in platelet concentrates from seropositive blood donors. Transfusion 2015;55:1249-55.
17. Cancino-Faure B, Fisa R, Riera C, et al. Where do Trypanosoma cruzi go? The distribution of parasites in blood components from fractionated infected whole blood. Transfusion 2016;56:2233-8.
18. Jimenez-Marco T, Ruiz-Alderton D, Bautista-Gili AM, et al. Role of riboflavin- and UV light-treated plasma in prevention of transfusion-related acute lung injury. Transfus Med Hemother 2014;41:172-5.
19. Jimenez-Marco T, Cancino-Faure B, Girona-Llobera E, et al. The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood. Transfusion 2017;57:1440-7.
20. Padhi S, Kemmis-Betty S, Rajesh S, et al. Blood transfusion: summary of NICE guidance. BMJ 2015;351:h5832.
21. Commission DIRECTIVE 2005;/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events [Internet]. London: European Medicines Agency; 2005 [cited 2018 Mar 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004485.pdf.
22. Spanish Accreditation Committee on Transfusion. Accreditation Standards for Blood Transfusion [Internet]. 4th ed. Madrid: Spanish Association of Haematology and Hemotherapy, Spanish Society of Blood Transfusion; 2012 [cited 2017 Jan 2]. Available from: https://www.catransfusion.es/estandares/index.html.
23. van der Meer PF, Couture C, Hervig T, et al. Experience with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres. Vox Sang 2017;112:9-17.
24. European Directorate for the Quality of Medicines & HealthCare. Guide for the preparation, use and quality assurance of blood components [Internet]. 19th ed. Strasbourg: Council of Europe, 2017 [cited 2017 Jan 2]. Available from: https://www.edqm.eu/en/blood-transfusion-guides-1608.html.
25. Abela MA, Fenning S, Maguire KA, et al. Bacterial contamination of platelet components not detected by BacT/ALERT®. Transfus Med 2018;28:65-70.
26. Ramirez-Arcos S, DiFranco C, McIntyre T, et al. Residual risk of bacterial contamination of platelets: six years of experience with sterility testing. Transfusion 2017;57:2174-81.
27. Weusten J, van Drimmelen H, Vermeulen M, et al. A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. Transfusion 2017;57:841-9.
28. Tedder RS, Ijaz S, Kitchen A, et al. Hepatitis E risks: pigs or blood—that is the question. Transfusion 2017;57:267-72.
29. Vanlandingham DL, Keil SD, Horne KM, et al. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013;53:284-90.
30. Cap AP, Pidcoke HF, Keil SD, et al. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 2016; 56:S6-15.
31. Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014;28:235-41.
32. Zeddies S, De Cuyper IM, van der Meer PF, et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014;54:2292-300.
33. van der Meer PF, Bontekoe IJ, Daal BB, et al. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? Transfusion 2015;55:1900-8.
34. Rebulla P, Vaglio S, Beccaria F, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion 2017;57:1171-83.
35. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50:2362-75.
36. Cook RJ, Heddle NM. Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations. Transfusion 2013;53:1843-55.
37. Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion 2003;43:2-6.
38. Panzer S, Jilma P. Methods for testing platelet function for transfusion medicine. Vox Sang 2011;101:1-9.
39. Kehrel BE, Brodde MF. State of the art in platelet function testing. Transfus Med Hemother 2013;40:73-86.
40. Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2017;7:CD009072.
41. Ypma PF, van der Meer PF, Heddle N, et al. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open 2016;6:e010156.
42. Cohn CS, Stubbs J, Schwartz J, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 2014;54:1927-34.
43. Heddle NM, Klama LN, Singer J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
44. Muylle L, Joos M, Wouters E, et al. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993;33:195-9.
45. Kacker S, Ness P, Savage JH, et al. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion 2013;53:2609-18.
46. Whitaker BI, Henry RA. The 2011 national blood collection and utilization survey report. Rockville (MD): US Department of Health and Human Services; 2013 [cited 2017 Jan 2]. Available from: https://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/11-nbcus-report.pdf.